ViaDerma Inc (VDRM)

[Potse]

VDRM...possible stem cell applications.....

The debt situation and the inability of the CEO to provide a clear/coherent picture of exactly what is occurring with the company obviously makes VDRM an extremely high-risk investment. But from a trading perspective, the stock does have its moments in the sunshine.

The press release this past week was an enouraging sign that additional news/activity may be forthcoming. Although most investor attention was directed toward the marijuana (CBD/THC) aspects of the PR, the fact that VDRM appears to have done some possible rebranding of its antibiotic product is something that caught my eye. According to the drug database, the marketing start date for Viabecline was November 8, 2016......

https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3e53ed13-b71e-494d-b292-5b1cac34689f&type=display

Prior to the recent press release, I accumulated some shares of VDRM because I thought the next push/promotion of the stock might involve the stem cell applications of tetracycline. It has gone largely unnoticed by VDRM investors, but over the last 2-3 months Phillips Company (from which VDRM licenses its tech/products) has been placing a PDF file on its website. The file chronicles the use of TetraStem (beginning July 2016) to treat a human spinal cord injury......

http://www.phillipscompany.4t.com/miranda.pdf